Scott explores the puzzling relationship between congenital blindness, schizophrenia, and autism, discussing potential explanations and the need for further research. Longer summary

Scott Alexander discusses the intriguing psychiatric trivia that congenitally blind people never develop schizophrenia, but are 50 times more likely to be diagnosed with autism. He explores this in the context of the diametrical model of autism vs. schizophrenia, which suggests these conditions are opposites in many ways. Scott speculates on possible explanations, including the idea that blindness might shift certain neural hyperparameters towards the autism end of a spectrum. He acknowledges the complexity of the issue and the need for further research, mentioning studies on sensory deprivation and its effects on both conditions. Shorter summary

Scott Alexander attempts to replicate a study linking beef jerky consumption to manic episodes in bipolar disorder, finding no significant relationship in his analysis of SSC survey data. Longer summary

Scott Alexander attempts to replicate a study that claimed beef jerky consumption could trigger manic episodes in bipolar disorder. He uses data from the 2019 Slate Star Codex survey to compare beef jerky consumption between people with and without a history of bipolar mania hospitalization. Contrary to the original study, Scott's analysis finds no significant relationship between beef jerky consumption and manic episodes. He discusses the limitations of his data, such as relying on self-reporting and having a smaller sample size of manic patients, but also notes some strengths like a more detailed measure of beef jerky consumption. Scott concludes by urging further research on this topic, highlighting the importance of replication in scientific studies. Shorter summary

Scott Alexander discusses new research suggesting ketamine's antidepressant effects may be linked to the opioid system, exploring the implications and potential future directions for depression treatment. Longer summary

Scott Alexander provides an update on ketamine research, discussing a new study that suggests ketamine's antidepressant effects may be related to the opioid system rather than NMDA receptors as previously thought. He compares this to a study on buprenorphine's effects on suicidal ideation and explores the implications of these findings. The post touches on the medical establishment's response, potential future directions for research and treatment, and the historical context of opiate use in medicine. Scott also raises questions about the relationship between opiates and depression, and the potential risks and benefits of using opioid-related treatments for depression. Shorter summary

Scott explores the theory that clozapine's unique effectiveness in treating schizophrenia may be due to its combined action on dopamine and glutamate systems, potentially opening avenues for safer treatments. Longer summary

This post explores why clozapine is considered uniquely effective among antipsychotic drugs for treating schizophrenia. Scott discusses recent research suggesting clozapine's superiority may be due to its action on the glutamate system, specifically as an NMDA receptor agonist, in addition to its dopamine-blocking effects. He explains that adding NMDA modulators to other antipsychotics improves their efficacy, but not when added to clozapine, possibly because clozapine already has this effect. The post speculates that if this theory is correct, it could lead to safer treatments combining standard antipsychotics with NMDA agonists, avoiding clozapine's serious side effects. However, Scott notes that more research is needed to confirm this hypothesis and overcome regulatory hurdles. Shorter summary

The post explores a new model for understanding mental disorders as networks of interconnected symptoms rather than discrete diseases with underlying causes. Longer summary

This post discusses a new way of understanding mental disorders proposed by Nuijten, Deserno, Cramer, and Borsboom (NDCB). Instead of viewing psychiatric conditions as discrete diseases with underlying causes, they suggest viewing them as networks of interconnected symptoms. The author explains how this model can account for various aspects of mental illness that are difficult to explain with traditional models, such as comorbidity, the effects of life stressors, and the polygenic nature of mental illnesses. The post also considers some limitations of this approach, particularly in explaining conditions like bipolar disorder and the rapid effects of treatments like ketamine. Despite these issues, the author finds the network model compelling as a way to understand the complexity of psychiatric disorders. Shorter summary

Scott examines new research on ketamine's antidepressant effects and its implications for understanding depression and evaluating psychiatric literature. Longer summary

This post discusses new research on ketamine's antidepressant effects, which suggests they are caused by a metabolite rather than ketamine itself. The author examines how this finding impacts previous research and understanding of ketamine's mechanism of action. He reviews studies on NMDA antagonists and finds mixed results, with some potential bias when conflicts of interest are present. The post concludes by reflecting on the implications for trusting psychiatric literature, especially in cases with conflicts of interest. Shorter summary

Scott Alexander shares insights and critiques from a psychiatry conference, covering topics from medication prescribing rights to new monitoring technologies and research methodologies. Longer summary

Scott Alexander humorously recounts his experience at a psychiatry conference, highlighting various issues in the field. He discusses the debate over psychologists prescribing medication, new technologies for monitoring schizophrenic patients, problems with certain study designs, the effectiveness of long-acting injectable antipsychotics, and the superiority of clozapine. He also touches on political lobbying in psychiatry and the influence of drug companies. The post is written with a mix of seriousness and sardonic humor, critiquing various aspects of psychiatric practice and research. Shorter summary